Carregando empresa
Just reported
Q3 2026 results
From ZAI LAB's results release of 5 de novembro de 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 108,2M
-6,8% y/y
+1,8% q/qGuided
—
No guide given
EPS, GAAP
Actual
-US$ 0,40
Guided
—
No guide given
Operating income, GAAP
Actual
-US$ 63M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes ZAI LAB is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$ 47,5BA+
EXELExelixis, Inc.US$ 17BA+
JAZZJazz Pharmaceuticals plcUS$ 15,4BA
HALOHalozyme Therapeutics, Inc.US$ 11,5BA+
TECHBIO-Techne CorpUS$ 11,4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
BIIBBiogen Inc.28 de out. de 2026BAGraded B, now A
Demonstrações financeiras completas →
Construído a partir dos próprios documentos de ZAI LAB Limited entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
